Clinical Trial Update: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vemurafenib in combination with lymphodepletion, adoptive cell transfer, and high-dose IL-2 for metastatic melanoma has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Adoptive cell transfer with lymphodepletion and high-dose interleukin-2
• Vemurafenib (vemurafenib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-03